News

The NDA represents the first potential treatment for pediatric patients with sickle cell disease, and the first potential new treatment in nearly 20 years for adult patients. Emmaus

The funding parties will provide $4 million over two years to fund research and development of AnTolRx's antigen-specific Targeted Nanoparticle Tolerance Therapeutics (TNTT) to treat immune disorders including

The company is developing the drug with Spanish pharmaceutical firm Ferrer. It has now recruited 130 patients from 11 clinical sites across three European countries. The trial, which

ImmuPharma has been requested to open a new site in Mauritius to participate in the current pivotal Phase III Lupuzor trial. Cap Research, a leading contract research organisation in

TIDES will enroll approximately 20,000 healthy children between the ages of four and 16 years living in dengue-endemic countries in Latin America and Asia. The study willevaluate the

With this approval, ORENCIA is the first biologic therapy with an indication in the European Union (EU) specifically applicable to the treatment of MTX-naive RA patients with highly

The company said it will continue developing the drug for posttraumatic stress disorder (PTSD). The preliminary topline results revealed that TNX-102 SL, taken once-daily at a 2.8-mg dosage,

Fulcrum will use Horizon's CRISPR screening platform to find targets for regulating gene expression in diseases with no current treatment options. The initial program features two projects with

The National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health, sponsored the two-stage study, which was carried out at the NIAID